Change And More Change: That’s What Brexit Means For Drug Companies
Executive Summary
The EU medicines network has issued a long list of changes that drug companies with activities in the UK will have to make if they are to continue to be located from a regulatory standpoint in the European Economic Area following Brexit. Aspects affected include the location of orphan designation holders, qualified persons for pharmacovigilance, companies’ manufacturing and batch release sites and maintenance of SME status.
You may also be interested in...
Ireland Fears Shortage Of Medicines Co-Labeled With UK Following Brexit
By encouraging and facilitating the joint labeling of medicines with the UK, Ireland has ensured the availability of the necessary human and veterinary medicines despite its small market size. But Brexit is causing concern that medicines for smaller patient populations may not be commercially viable if they have to be packaged separately for the Irish market.
Industry Response To Brexit Survey Key For Future Planning, Says EMA
Sponsors of centrally authorized medicines in the EU are being urged to respond to a survey by the European Medicines Agency aimed at gauging industry's preparedness for Brexit. Companies have until Feb. 9 to complete survey, which the EMA says is critical to help with resource planning and ensuring a smooth transition.
EMA Explains How To Make Brexit-Related MA Changes, As Industry Bodies Urge Transition Period
The EMA has produced further guidance for pharmaceutical companies on the changes they will need to make as a result of Brexit, focusing on activities such as transfers of marketing authorizations and orphan designations, and changes to personnel responsible for pharmacovigilance and batch recalls. Meanwhile, UK and European industry bodies say there is not enough time to make the necessary changes and that a transition period is needed.